283 related articles for article (PubMed ID: 31189573)
1. Sepsis-Induced State of Immunoparalysis Is Defined by Diminished CD8 T Cell-Mediated Antitumor Immunity.
Danahy DB; Kurup SP; Winborn CS; Jensen IJ; Harty JT; Griffith TS; Badovinac VP
J Immunol; 2019 Aug; 203(3):725-735. PubMed ID: 31189573
[TBL] [Abstract][Full Text] [Related]
2. Cutting Edge: Polymicrobial Sepsis Has the Capacity to Reinvigorate Tumor-Infiltrating CD8 T Cells and Prolong Host Survival.
Danahy DB; Jensen IJ; Griffith TS; Badovinac VP
J Immunol; 2019 May; 202(10):2843-2848. PubMed ID: 30971442
[TBL] [Abstract][Full Text] [Related]
3. Polymicrobial Sepsis Increases Susceptibility to Chronic Viral Infection and Exacerbates CD8+ T Cell Exhaustion.
Condotta SA; Khan SH; Rai D; Griffith TS; Badovinac VP
J Immunol; 2015 Jul; 195(1):116-25. PubMed ID: 25980007
[TBL] [Abstract][Full Text] [Related]
4. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
[TBL] [Abstract][Full Text] [Related]
5. Characterization of CD103
Han L; Gao QL; Zhou XM; Shi C; Chen GY; Song YP; Yao YJ; Zhao YM; Wen XY; Liu SL; Qi YM; Gao YF
Cancer Immunol Immunother; 2020 Aug; 69(8):1493-1504. PubMed ID: 32285170
[TBL] [Abstract][Full Text] [Related]
6. Subsets of exhausted CD8
Miller BC; Sen DR; Al Abosy R; Bi K; Virkud YV; LaFleur MW; Yates KB; Lako A; Felt K; Naik GS; Manos M; Gjini E; Kuchroo JR; Ishizuka JJ; Collier JL; Griffin GK; Maleri S; Comstock DE; Weiss SA; Brown FD; Panda A; Zimmer MD; Manguso RT; Hodi FS; Rodig SJ; Sharpe AH; Haining WN
Nat Immunol; 2019 Mar; 20(3):326-336. PubMed ID: 30778252
[TBL] [Abstract][Full Text] [Related]
7. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer.
Matsuzaki J; Gnjatic S; Mhawech-Fauceglia P; Beck A; Miller A; Tsuji T; Eppolito C; Qian F; Lele S; Shrikant P; Old LJ; Odunsi K
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7875-80. PubMed ID: 20385810
[TBL] [Abstract][Full Text] [Related]
9. Expansion of Tumor-Infiltrating CD8
Fernandez-Poma SM; Salas-Benito D; Lozano T; Casares N; Riezu-Boj JI; Mancheño U; Elizalde E; Alignani D; Zubeldia N; Otano I; Conde E; Sarobe P; Lasarte JJ; Hervas-Stubbs S
Cancer Res; 2017 Jul; 77(13):3672-3684. PubMed ID: 28522749
[TBL] [Abstract][Full Text] [Related]
10. Functional tumor specific CD8 + T cells in spleen express a high level of PD-1.
Wang Z; Chen T; Lin W; Zheng W; Chen J; Huang F; Xie X
Int Immunopharmacol; 2020 Mar; 80():106242. PubMed ID: 32014811
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
[TBL] [Abstract][Full Text] [Related]
12. TIGIT and PD1 Co-blockade Restores ex vivo Functions of Human Tumor-Infiltrating CD8
Ge Z; Zhou G; Campos Carrascosa L; Gausvik E; Boor PPC; Noordam L; Doukas M; Polak WG; Terkivatan T; Pan Q; Takkenberg RB; Verheij J; Erdmann JI; IJzermans JNM; Peppelenbosch MP; Kraan J; Kwekkeboom J; Sprengers D
Cell Mol Gastroenterol Hepatol; 2021; 12(2):443-464. PubMed ID: 33781741
[TBL] [Abstract][Full Text] [Related]
13. Immune-Checkpoint Blockade Opposes CD8
Pfannenstiel LW; Diaz-Montero CM; Tian YF; Scharpf J; Ko JS; Gastman BR
Cancer Immunol Res; 2019 Mar; 7(3):510-525. PubMed ID: 30728151
[TBL] [Abstract][Full Text] [Related]
14. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
[TBL] [Abstract][Full Text] [Related]
15. Intratumoral Tcf1
Siddiqui I; Schaeuble K; Chennupati V; Fuertes Marraco SA; Calderon-Copete S; Pais Ferreira D; Carmona SJ; Scarpellino L; Gfeller D; Pradervand S; Luther SA; Speiser DE; Held W
Immunity; 2019 Jan; 50(1):195-211.e10. PubMed ID: 30635237
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial immunotherapy induces tumor-infiltrating CD8
Van Braeckel-Budimir N; Dolina JS; Wei J; Wang X; Chen SH; Santiago P; Tu G; Micci L; Al-Khami AA; Pfister S; Ram S; Sundar P; Thomas G; Long H; Yang W; Potluri S; Salek-Ardakani S
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34903555
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models.
Leone RD; Sun IM; Oh MH; Sun IH; Wen J; Englert J; Powell JD
Cancer Immunol Immunother; 2018 Aug; 67(8):1271-1284. PubMed ID: 29923026
[TBL] [Abstract][Full Text] [Related]
18. Virus-Specific CD8
Erkes DA; Smith CJ; Wilski NA; Caldeira-Dantas S; Mohgbeli T; Snyder CM
J Immunol; 2017 Apr; 198(7):2979-2988. PubMed ID: 28202614
[TBL] [Abstract][Full Text] [Related]
19. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
20. PD-1 and LAG-3 Dominate Checkpoint Receptor-Mediated T-cell Inhibition in Renal Cell Carcinoma.
Zelba H; Bedke J; Hennenlotter J; Mostböck S; Zettl M; Zichner T; Chandran A; Stenzl A; Rammensee HG; Gouttefangeas C
Cancer Immunol Res; 2019 Nov; 7(11):1891-1899. PubMed ID: 31484656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
